eCase Study Videos

In this 15-minute on-demand presentation, learn how Accuplex SARS-CoV-2 Reference Materials are meeting the immediate need for validating the performance of coronavirus assays. The focus of this presentation is on the technology, the importance of early detection, and helping every lab accelerate go-live-launch.

Conventional animal testing for quality control of vaccines is lengthy and may require large numbers of animals. To address these limitations, the use of specific biomarkers to evaluate batch-to-batch consistency and the safety of vaccines has been proposed. Specific panels could also be used as novel markers to evaluate adjuvant safety profiles and for safety assessment of inoculation routes.

The QuantiGene multiplex gene expression assays are based on branched DNA (bDNA) technology and allow for direct-from-sample transcriptional profiling.  These assays have been used to develop more reliable and robust parameters for testing than conventional animal tests. In addition, with the advent of nucleic acid vaccines such as mRNA vaccines, the QuantiGene technology has been used to evaluate the safety of delivery systems and to monitor the biodistribution of these nucleic acids after administration via different routes. These are important aspects to be determined to demonstrate that the safety profiles of these RNA vaccines are comparable to traditional vaccines.

Here we discuss some of these recent advances in evaluation of vaccine quality control and safety utilizing the QuantiGene multiplex gene expression assays.

In just a few months COVID-19 has risen from a regional crisis to a global threat, and drug makers are now scrambling to develop vaccines aimed at thwarting a pandemic. To meet this urgent and life-threatening situation, vaccine developers are actively seeking the most efficient and robust production platforms to accelerate development timelines. Throughput, productivity, and scalability of the expression platform as well as the availability of well-documented production cell lines are key selection criteria when initiating a vaccine development campaign under such urgent circumstances. To this end, the Gibco Expi Expression Systems are complete platforms that can accelerate vaccine development by enabling rapid, high-yield, and scalable production of proteins, viral antigens and viral-like particles from mammalian (ExpiCHO and Expi293) and insect (ExpiSf) cells. By providing flexible and highly productive expression systems for three different cell hosts that employ optimized and chemically defined components, the Expi systems support every stage of vaccine development. This unified, end-to-end approach reduces key product quality risks during development as one can use the same cell line from research to large-scale production while streamlining process development by utilizing integrated reagents for unmatched performance.